July 2018
Volume 59, Issue 9
ARVO Annual Meeting Abstract  |   July 2018
Use of a novel Rpgr-null mouse line allows rapid efficacy evaluation of gene augmentation therapy
Author Affiliations & Notes
  • Zhijian Wu
    NIH/NEI, Gaithersburg, Maryland, United States
  • Myung Kuk Joe
    NIH/NEI, Gaithersburg, Maryland, United States
  • Wenhan Yu
    NIH/NEI, Gaithersburg, Maryland, United States
  • Suja Hiriyanna
    NIH/NEI, Gaithersburg, Maryland, United States
  • Footnotes
    Commercial Relationships   Zhijian Wu, None; Myung Kuk Joe, None; Wenhan Yu, None; Suja Hiriyanna, None
  • Footnotes
    Support  NIH/NEI Intramural Research Program
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 4528. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Zhijian Wu, Myung Kuk Joe, Wenhan Yu, Suja Hiriyanna; Use of a novel Rpgr-null mouse line allows rapid efficacy evaluation of gene augmentation therapy. Invest. Ophthalmol. Vis. Sci. 2018;59(9):4528. doi: https://doi.org/.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose :
Mutations in the RPGR gene account for about 70 percent of X-linked retinitis pigmentosa (XLRP) and are one of the most common causes of all RP cases. Gene augmentation therapy was shown to be capable of preserving retinal function and structure in canine or murine models of Rpgr deficiency. However, a long time period (12 to 24 months) is usually needed for preclinical efficacy study in mice with Rpgr mutations due to the slow degeneration of their retinas. In a recent report (Rao et al., Hum Mol Genet, 2016; 25: 2005), Rpgrko/Y mice with a heterozygous hypomorphic allele of Cep290 (Cep290rd16/+) exhibited much earlier onset and faster progression of retinal degeneration and dysfunction than Rpgrko/Y mice. This mouse line (Rpgrko/Y;Cep290rd16/+) was used in the current study to test if therapeutic effects can be captured in a short time period after treatment.

Methods : Each mouse, at 6 weeks of age, received subretinal injection of one micro liter (µL) AAV9-RPGR vector at a dose of 1x109 vector genomes (vg) in one eye and the same volume of vehicle in the other eye. Electroretinogram (ERG) and optical coherence tomography (OCT) were performed on the treated mice when they were about 3 months (6 weeks after vector injection) and 7 months of age. At the end of the study, the mice were sacrificed for immunofluorescence analysis. Paired t test was used for statistics.

Results :
The mice exhibited significantly higher ERG amplitudes in the vector-treated eyes than the control eyes starting from 3 months of age. OCT analyses revealed longer outer segments (OS)/inner segments (IS) in the vector-treated eyes at 3 months of age, and thicker outer nuclear layers (ONL, or photoreceptor layer) at 7 months of age. In the vehicle-treated retinas, M cone opsin was not only found in the OS, its normal subcellular localization, but also in the IS and the perinuclear and synaptic regions. In contrast, M opsin was almost exclusively observed in the OS in the vector-treated retinas, similar to the wild-type retina.

Conclusions : Therapeutic effects can be observed in the Rpgrko/Y;Cep290rd16/+ mice at 6 weeks after RPGR vector administration, which is much faster than previous studies using Rpgrko/Y mice. Use of the Rpgrko/Y;Cep290rd16/+ mouse line would allow rapid efficacy evaluation of gene therapy treatment.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.